KIT and melanoma: In 2013, Todd et al. reported that secondary c-KIT mutations can confer acquired resistance to imatinib and nilotinib in c-KIT mutant melanoma cells (M230 c-Kit L576P) and suggested alternative RTK inhibitors or inhibitors targeting the MAPK and PI3K signaling cascades to overcome resistance (Table 1) [55].